These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 20345933

  • 1. Alterations of intracerebral γ-aminobutyric acid (GABA) levels by titration with levetiracetam in patients with focal epilepsies.
    Doelken MT, Hammen T, Bogner W, Mennecke A, Stadlbauer A, Boettcher U, Doerfler A, Stefan H.
    Epilepsia; 2010 Aug; 51(8):1477-82. PubMed ID: 20345933
    [Abstract] [Full Text] [Related]

  • 2. Effects of vigabatrin on brain GABA+/CR signals in patients with epilepsy monitored by 1H-NMR-spectroscopy: responder characteristics.
    Mueller SG, Weber OM, Duc CO, Weber B, Meier D, Russ W, Boesiger P, Wieser HG.
    Epilepsia; 2001 Jan; 42(1):29-40. PubMed ID: 11207782
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group.
    Ben-Menachem E, Falter U.
    Epilepsia; 2000 Oct; 41(10):1276-83. PubMed ID: 11051122
    [Abstract] [Full Text] [Related]

  • 4. Levetiracetam has no acute effects on brain gamma-aminobutyric acid levels.
    Kuzniecky R, Pan J, Burns A, Devinsky O, Hetherington H.
    Epilepsy Behav; 2008 Feb; 12(2):242-4. PubMed ID: 18286712
    [Abstract] [Full Text] [Related]

  • 5. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam.
    Kinirons P, McCarthy M, Doherty CP, Delanty N.
    Seizure; 2006 Sep; 15(6):387-92. PubMed ID: 16766211
    [Abstract] [Full Text] [Related]

  • 6. Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA).
    Stefan H, Wang-Tilz Y, Pauli E, Dennhöfer S, Genow A, Kerling F, Lorber B, Fraunberger B, Halboni P, Koebnick C, Gefeller O, Tilz C.
    Epilepsia; 2006 Mar; 47(3):516-22. PubMed ID: 16529615
    [Abstract] [Full Text] [Related]

  • 7. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
    Wu XY, Hong Z, Wu X, Wu LW, Wang XF, Zhou D, Zhao ZX, Lv CZ.
    Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
    [Abstract] [Full Text] [Related]

  • 8. High-field MRS study of GABA+ in patients with migraine: response to levetiracetam treatment.
    Li Q, Chen C, Gong T.
    Neuroreport; 2018 Aug 15; 29(12):1007-1010. PubMed ID: 29889154
    [Abstract] [Full Text] [Related]

  • 9. Levetiracetam as add-on therapy in different subgroups of "benign" idiopathic focal epilepsies in childhood.
    von Stülpnagel C, Kluger G, Leiz S, Holthausen H.
    Epilepsy Behav; 2010 Feb 15; 17(2):193-8. PubMed ID: 20045383
    [Abstract] [Full Text] [Related]

  • 10. Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study.
    Alsaadi TM, Shatzel A, Marquez AV, Jorgensen J, Farias S.
    Seizure; 2005 Mar 15; 14(2):139-42. PubMed ID: 15694569
    [Abstract] [Full Text] [Related]

  • 11. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
    Steinhoff BJ, Somerville ER, Van Paesschen W, Ryvlin P, Schelstraete I.
    Epilepsy Res; 2007 Aug 15; 76(1):6-14. PubMed ID: 17681453
    [Abstract] [Full Text] [Related]

  • 12. Levetiracetam add-on therapy in Japanese patients with refractory partial epilepsy.
    Tanaka S, Tanaka T.
    Epileptic Disord; 2013 Jun 15; 15(2):132-41. PubMed ID: 23774199
    [Abstract] [Full Text] [Related]

  • 13. Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy.
    Rocamora R, Wagner K, Schulze-Bonhage A.
    Seizure; 2006 Sep 15; 15(6):428-33. PubMed ID: 16837220
    [Abstract] [Full Text] [Related]

  • 14. Levetiracetam in refractory epilepsy: a prospective observational study.
    Mohanraj R, Parker PG, Stephen LJ, Brodie MJ.
    Seizure; 2005 Jan 15; 14(1):23-7. PubMed ID: 15642496
    [Abstract] [Full Text] [Related]

  • 15. Disfluent speech in patients with partial epilepsy: beneficial effect of levetiracetam.
    Sechi G, Cocco GA, D'Onofrio M, Deriu MG, Rosati G.
    Epilepsy Behav; 2006 Nov 15; 9(3):521-3. PubMed ID: 16971185
    [Abstract] [Full Text] [Related]

  • 16. Use of levetiracetam in hospitalized patients.
    Falip M, Carreño M, Amaro S, Donaire A, Delgado R, Toledo M, Maestro I.
    Epilepsia; 2006 Dec 15; 47(12):2186-8. PubMed ID: 17201722
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of levetiracetam in the treatment of Panayiotopoulos syndrome.
    García C, Rubio G.
    Epilepsy Res; 2009 Aug 15; 85(2-3):318-20. PubMed ID: 19423296
    [Abstract] [Full Text] [Related]

  • 18. The effect of levetiracetam monotherapy on subjective sleep quality and objective sleep parameters in patients with epilepsy: compared with the effect of carbamazepine-CR monotherapy.
    Cho YW, Kim DH, Motamedi GK.
    Seizure; 2011 May 15; 20(4):336-9. PubMed ID: 21316267
    [Abstract] [Full Text] [Related]

  • 19. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
    Peltola J, Coetzee C, Jiménez F, Litovchenko T, Ramaratnam S, Zaslavaskiy L, Lu ZS, Sykes DM, Levetiracetam XR N01235 Study Group.
    Epilepsia; 2009 Mar 15; 50(3):406-14. PubMed ID: 19317886
    [Abstract] [Full Text] [Related]

  • 20. [Clinical efficacy of the novel antiepileptic agent levetiracetam: evaluation in patients with localization-related epilepsy].
    Yamazoe T, Fujimoto A, Yamazaki M, Yokota T, Okanishi T, Uchiyama T, Ohashi T, Tanaka T, Enoki H, Yamamoto T.
    Brain Nerve; 2012 Oct 15; 64(10):1169-74. PubMed ID: 23037607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.